EPS for ContraFect Corporation (CFRX) Expected At $-0.10

October 14, 2018 - By Marie Mckinney

ContraFect Corporation (NASDAQ:CFRX) Logo

Analysts expect ContraFect Corporation (NASDAQ:CFRX) to report $-0.10 EPS on November, 8.They anticipate $0.14 EPS change or 350.00 % from last quarter’s $0.04 EPS. After having $-0.10 EPS previously, ContraFect Corporation’s analysts see 0.00 % EPS growth. The stock increased 2.51% or $0.05 during the last trading session, reaching $2.04. About 94,630 shares traded. ContraFect Corporation (NASDAQ:CFRX) has risen 94.57% since October 14, 2017 and is uptrending. It has outperformed by 78.95% the S&P500.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. The company has market cap of $162.00 million. The Company’s lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of human influenza. It currently has negative earnings. The firm has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza.

More important recent ContraFect Corporation (NASDAQ:CFRX) news were published by: Nasdaq.com which released: “ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF …” on September 25, 2018, also Seekingalpha.com published article titled: “Contrafect: A New Anti-Microbial Treatment Paradigm”, Prnewswire.com published: “Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018” on October 03, 2018. More interesting news about ContraFect Corporation (NASDAQ:CFRX) was released by: Globenewswire.com and their article: “ContraFect to Present at Two Upcoming Investor Conferences” with publication date: September 20, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.